{"id":11162,"date":"2022-08-22T00:00:00","date_gmt":"2022-08-22T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/la-triple-therapie-a-base-de-daratumumab-montre-des-avantages-pour-le-myelome-multiple-recidivant-refractaire-en-anglais-seulement\/"},"modified":"2025-08-19T08:28:15","modified_gmt":"2025-08-19T13:28:15","slug":"la-triple-therapie-a-base-de-daratumumab-montre-des-avantages-pour-le-myelome-multiple-recidivant-refractaire-en-anglais-seulement","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2022\/08\/22\/la-triple-therapie-a-base-de-daratumumab-montre-des-avantages-pour-le-myelome-multiple-recidivant-refractaire-en-anglais-seulement\/","title":{"rendered":"La triple th\u00e9rapie \u00e0 base de daratumumab montre des avantages pour le my\u00e9lome multiple r\u00e9cidivant\/r\u00e9fractaire  (en anglais seulement)"},"content":{"rendered":"<p>Results from a recent real-world analysis suggest possible benefits with early use of daratumumab-based triplet therapies in patients with relapsed\/refractory (RR) multiple myeloma (MM). The study\u2019s findings were reported in the journal&nbsp;<em>Leukemia Research Reports<\/em>.<\/p>\n<p><strong><a href=\"https:\/\/www.hematologyadvisor.com\/home\/topics\/myeloma\/multiple-myeloma-daratumumab-triplet-therapy-shows-benefit-treatment\/?utm_source=newsletter&amp;utm_medium=email&amp;utm_campaign=NWLTR_HEM_UPDT_080922_RM&amp;hmEmail=t4mjb5pDq%2FT4EMHH1f6XPf%2FulL3aOOCE&amp;sha256email=f8197e3c3fe7c7a089d6a639a92231583494d8f5d9f107f3c8deff7a0952d05a&amp;hmSubId=&amp;NID=\" target=\"_blank\" rel=\"noopener\">Cliquez ici pour lire la suite<\/a><\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Results from a recent real-world analysis suggest possible benefits with early use of daratumumab-based triplet therapies in patients with relapsed\/refractory (RR) multiple myeloma (MM). The study\u2019s findings were reported in the journal&nbsp;Leukemia Research Reports. Cliquez ici pour lire la suite.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11162","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11162"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11162\/revisions"}],"predecessor-version":[{"id":31285,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11162\/revisions\/31285"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}